Wealth Effects LLC Sells 8,200 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Wealth Effects LLC cut its position in Autolus Therapeutics plc (NASDAQ:AUTL) by 16.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,800 shares of the company’s stock after selling 8,200 shares during the quarter. Wealth Effects LLC’s holdings in Autolus Therapeutics were worth $101,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Exchange Traded Concepts LLC raised its stake in Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after acquiring an additional 3,740 shares in the last quarter. Bellevue Group AG grew its holdings in shares of Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. State Street Corp increased its position in Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after purchasing an additional 10,401 shares in the last quarter. ProShare Advisors LLC bought a new position in Autolus Therapeutics in the 2nd quarter valued at approximately $43,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at approximately $51,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Down 2.7 %

NASDAQ AUTL opened at $2.20 on Wednesday. The company has a market capitalization of $585.40 million, a price-to-earnings ratio of -1.82 and a beta of 2.05. Autolus Therapeutics plc has a twelve month low of $2.07 and a twelve month high of $7.37. The stock has a fifty day simple moving average of $2.57 and a 200 day simple moving average of $3.48.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company posted ($0.26) earnings per share. Research analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AUTL has been the subject of several research analyst reports. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.